A Phase 2a, Multi-center, Placebo-Controlled, Randomized, Assessor-blind Study to Assess the Safety & Efficacy of Parenteral TK-90 or Parenteral TK-90 Placebo to Patients Receiving Radiotherapy for Non-Metastatic Squamous Cell Carcinoma of Head and Neck.
Latest Information Update: 16 Aug 2023
At a glance
- Drugs TK 112690 (Primary)
- Indications Mucositis
- Focus Adverse reactions
- Sponsors Tosk
Most Recent Events
- 08 Aug 2023 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.
- 08 Aug 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Sep 2023.
- 08 Aug 2023 Status changed from recruiting to active, no longer recruiting.